gammaCore Sapphire
Acute treatment of migraine
Key Facts
About electroCore
Founded in 2005, electroCore is a leader in non-invasive neuromodulation, developing and commercializing its gammaCore nVNS platform. The company has achieved FDA clearances, CE marks, and other international approvals for its reusable medical device, generating revenue while expanding its clinical pipeline into new indications like PTSD and metabolic disorders. With a strong intellectual property portfolio of over 200 patents and a seasoned leadership team, electroCore aims to establish nVNS as a foundational therapy across multiple therapeutic areas.
View full company profileAbout electroCore
Founded in 2005, electroCore is a leader in non-invasive neuromodulation, developing and commercializing its gammaCore nVNS platform. The company has achieved FDA clearances, CE marks, and other international approvals for its reusable medical device, generating revenue while expanding its clinical pipeline into new indications like PTSD and metabolic disorders. With a strong intellectual property portfolio of over 200 patents and a seasoned leadership team, electroCore aims to establish nVNS as a foundational therapy across multiple therapeutic areas.
View full company profileAbout electroCore
Founded in 2005, electroCore is a leader in non-invasive neuromodulation, developing and commercializing its gammaCore nVNS platform. The company has achieved FDA clearances, CE marks, and other international approvals for its reusable medical device, generating revenue while expanding its clinical pipeline into new indications like PTSD and metabolic disorders. With a strong intellectual property portfolio of over 200 patents and a seasoned leadership team, electroCore aims to establish nVNS as a foundational therapy across multiple therapeutic areas.
View full company profileTherapeutic Areas
Other Acute treatment of migraine Drugs
| Drug | Company | Phase |
|---|---|---|
| PH80 | Vistagen Therapeutics | Preclinical |